Improved Glycemic Control in Diabetic Patients in Hemodialysis Using Continuous Glucose Monitoring (CGM)
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 23
- 试验地点
- 2
- 主要终点
- time below range (CGM)
研究概览
简要总结
The 16-week trial is an open-label cross-over trial which includes heamodialysis patients with T2D and T1D on insulin therapy. During one period, patients carry a non-blinded CGM. In the other period they follow standard procedures (the last two weeks with a blinded CGM). The patients and the dialysis staff can use the CGM measures to regulate insulin and food intake during the non-blinded weeks. The research group will collect the CGM-data during the trial.
详细描述
Background: Managing diabetes is often problematic in haemodialysis (HD) patients. Low blood glucose is especially common during treatment. Typically, the patient's blood sugar is only measured during treatment if considered relevant. Otherwise, HbA1c is used to control diabetes - a method associated with uncertain in HD patients. An alternative or supplement to the current management of diabetes could be CGM which enables closer observation and management of the diabetes disease. Despite the possibilities of using CGM, there are still few studies in the field which examine the importance of CGM data in relation to the management of diabetes in HD patients.
Aims: To investigate whether the use of CGM data can prevent low blood sugar levels during HD and examins whether the use of CGM data can improve the management of diabetes in HD patients. Furthermore, it is found relevant to investigate if CGM data, selected blood test responses, treatment data, personal data and information about medicines can be used to predict low blood sugar during HD using an algorithm. Thus, the study also aims to develop and validate such an algorithm.
Setting: The trial will be conducted at two dialysis wards (Aalborg and Hjørring) at Aalborg University Hospital.
Subjects: Heamodialysis patients with T1D and T2D on insulin therapy.
Study design: The 16-week trial is an open-label cross-over trial. During one period, patients carry a non-blinded CGM. In the other period they follow standard procedures (the last two weeks with a blinded CGM). The patients and the dialysis staff can use the CGM measures to regulate insulin and food intake during the non-blinded weeks. The research group will collect the CGM-data during the trial. The last four weeks include baseline measures (blinded CGM).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •≥ 18 years
- •Chronically ill heamodialysis patients (heamodialysis or heamodiafiltration - treatment)der modtager HD- eller hæmodiafiltrationsbehandling på dialyseafsnit,--
- •Patients at dialysis wards in Aalborg and Hjørring, Aalborg University Hospital (center and home patients)
- •T1D or T2D and in treatment with insulin
- •Being able to use CGM equipment
- •Signed consent
排除标准
- •Pregnancy or breastfeeding,
- •Terms that, in the opinion of the investigator or subinvestigators, render the participant unfit to conduct the trial, including lack of understanding of the trial or lack of physical or cognitive ability to participate
- •Patients undergoing peritoneal dialysis (PD) or heamofiltration dialysis (HF)
- •Acute HD treatment
- •Gestational diabetes
结局指标
主要结局
time below range (CGM)
时间窗: 6 weeks of treatment in each of the two treatment periods
Change in time below range (CGM) (\< 3.0 mmol/L)
次要结局
- Time in range (CGM)(6 weeks of treatment in each of the two treatment periods)
- Time in borderline low range (CGM)(6 weeks of treatment in each of the two treatment periods)
- Time above range (CGM)(6 weeks of treatment in each of the two treatment periods)
- Glucose variability(6 weeks of treatment in each of the two treatment periods)
- Sensitivity and specificity of algorithm(Through study completion, an average of one year)
- Time above range (CGM) (high)(6 weeks of treatment in each of the two treatment periods)
- Concentration of HbA1c(6 weeks of treatment in each of the two treatment periods)
研究者
Peter Vestergaard
MD, professor
Aalborg University Hospital